Our major areas of interest are:

Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Haugen MH, Engebraaten O (2025)
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy
Breast Cancer Res, 27 (1), 143
DOI 10.1186/s13058-025-02092-9, PubMed 40790765

Valsala Kumari R, Pandya AD, Pettersen SJ, Kvalvaag A, Myrann AG, Ghiarasim R, Rotaru A, Dimofte MG, Skotland T, Sandvig K, Mari Mælandsmo G, Iversen TG (2025)
Evaluation of HER2 Targeted Poly(Ethylene Glycol)-Poly(L-histidine) Copolymer Micelles in Breast Cancer Models
Macromol Biosci, e00047 (in press)
DOI 10.1002/mabi.202500047, PubMed 40719176

Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Øynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Mælandsmo GM, Egeland EV, Prasmickaite L (2025)
Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer
Breast Cancer Res, 27 (1), 131
DOI 10.1186/s13058-025-02082-x, PubMed 40660361